About the Company
Nektar Therapeutics (Nektar) is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NKTR News
Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test
Nektar Therapeutics' rezpegaldesleukin is now in two phase 2 studies, one in atopic dermatitis and one in alopecia areata.
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
Nektar Therapeutics NKTR announced that it has initiated a new mid-stage study that will evaluate its pipeline candidate, ...
Biotech naming trends bypass 'buzzwords and business speak' to build whimsical, memorable brands
In a world overrun by innovative biotechs, be a Mammoth Biosciences. Or a Nutcracker Therapeutics. Or Viking Therapeutics or ...
Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript
Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.22 EPS, expectations were $-0.2. NKTR isn't one of the 30 most popular stocks among hedge funds at the end of the third ...
Nektar: Q4 Earnings Snapshot
SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Monday reported a loss of $42.1 million in its fourth quarter. On a per-share basis, the San Francisco-based company ...
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
SAN FRANCISCO, March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease ...
Loading the latest forecasts...